BioArctic AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 88
- Market Cap
- -
- Website
- http://www.bioarctic.se
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients with Parkinson's Disease
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- BioArctic AB
- Target Recruit Count
- 24
- Registration Number
- NCT06671938
- Locations
- 🇪🇸
Hospital Universitari General de Catalunya, Sant Cugat del Valles, Barcelona, Spain
🇵🇱Centrum Medyczyne Neuromed Sp. z o.o., Bydgoszcz, Poland
🇵🇱Specjalistyczne Gabinety Sp. z o.o., Krakow, Poland
Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects
Phase 1
- Conditions
- Spinal Cord Injury
- Interventions
- Procedure: SC0806 and rehabilitationOther: Rehabilitation only
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- BioArctic AB
- Target Recruit Count
- 27
- Registration Number
- NCT02490501
- Locations
- 🇸🇪
Karolinska University Hospital and RSS, Stockholm, Sweden
© Copyright 2025. All Rights Reserved by MedPath